Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver cancer surgery Follow-Up: could a targeted chemo shot keep cancer away?

NCT ID NCT07417397

Disease control Sponsor: Guangxi Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether giving a targeted chemotherapy treatment (TACE) after liver cancer surgery can prevent the cancer from coming back. It involves 442 patients with high-risk features for recurrence. Half will receive TACE, and the other half will have intensive monitoring only, with researchers comparing how long each group stays cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lobaplatin and ethiodized poppyseed oil (chemotherapy) delivered via transarterial chemoembolization (TACE)
What this could lead to
If successful, this could provide a standard way to lower the chance of liver cancer returning after surgery, improving long-term survival.
What could go wrong
This is a large Phase 3 trial, but previous studies have disagreed on whether adjuvant TACE helps. The procedure also carries risks like liver damage or side effects from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 442 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 at enrollment; * Child-Pugh class A or B7 (score 5-7); * having undergone radical hepatic resection at one of the study centers; * histopathologically confirmed HCC; * undergo hepatic angiography 4-8 weeks after surgery, with confirmation of no intrahepatic tumor staining; * have no prior systemic anti-tumor therapy for HCC; * have adequate organ and bone marrow function; * estimated life expectancy \>6 months; * present with at least one high-risk factor for recurrence (such as tumor rupture; maximum tumor diameter \>5 cm; multifocal tumors; microvascular invasion on postoperative pathology; Vp1/Vp2 portal vein invasion; lymph node metastasis confirmed by postoperative pathology; positive or narrow surgical margin; and Edmondson grade Ⅲ-Ⅳ differentiation). Exclusion Criteria: * absence of pathological confirmation of HCC; * diagnosis of other malignancies within the 5 years prior to enrollment; * a history of hepatic encephalopathy, liver transplantation, pleural effusion, ascites, or pericardial effusion with clinical symptoms after curative hepatectomy, as well as a history of drug allergy, active pulmonary tuberculosis, active syphilis infection, autoimmune disease, or long-term glucocorticoid use; * participants who have experienced severe infections within 4 weeks before the first dose, or who have previously received systemic anti-tumor therapy; * pregnant or lactating women are ineligible for participation; * participants who are unable to comply with the treatment regimen or complete the follow-up requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adjuvant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adjuvant Hepatocellular carcinoma Transarterial chemoembolization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.